ArticlebioRxiv : the preprint server for biology2025
Modeling the structure-conditioned sequence landscape for large-scale protein design with TriFlow.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Generative models have revolutionized computational protein design, and the design of high-quality sequences given backbone structure is a critical component for success. Current state-of-the-art design pipelines utilize sequence design methods with local structural context and autoregressive generation. To improve efficiency and quality of sequence design, we developed TriFlow, a model that combines a RoseTTAFold-like three-track architecture for global structural context with discrete flow-matching for efficient few-step sequence generation. We trained TriFlow on a large dataset of interacting protein chains from PDB and interacting domains from AlphaFold protein structure Database to enrich its knowledge of natural protein/domain interfaces. While showing improvements across diverse benchmarks, TriFlow's primary advance is in de novo binder design, where it boosts the in silico success rate of state-of-the-art design pipelines such as BindCraft. We demonstrated this by conducting a large-scale benchmark, generating and validating binders for over 500 diverse protein targets. By leveraging the model to explore the designed sequence landscape, we discovered that we can effectively highlight functional active sites, by contrasting constraints learned by the structure-conditioned model with natural evolutionary profiles. As a practical demonstration of its capabilities, we apply our pipeline to systematically design specific binders against human class I cytokines family, computationally optimizing for on-target affinity while minimizing off-target interactions, demonstrating that specificity also scales with inference time computational budget. TriFlow thus provides a robust framework for both large-scale protein engineering and for exploring the fundamental principles of the structure-conditioned sequence landscape.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.